Molecular prognostic markers, including IgVH mutation status, ZAP70 and CD38 expression, and interphase cytogenetic aberrations, identify subgroups of CLL patients with varying clinical outcomes. Here, CD38 is linked to B-cell chronic lymphocytic leukemia.